Patents by Inventor Nathan D. Thomsen

Nathan D. Thomsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies that target HIV GP120 and methods of use
    Patent number: 11987617
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: May 21, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Nathan D. Thomsen
  • ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
    Publication number: 20240034774
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Application
    Filed: August 4, 2023
    Publication date: February 1, 2024
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 11655285
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 11597759
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 7, 2023
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Matthew R. Schenauer, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE
    Publication number: 20230056252
    Abstract: Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 23, 2023
    Inventors: Manuel Baca, Wade S. Blair, Brian A. Carr, Sheila B. Clancy, Joshua Goldsmith, Magdeleine S. Hung, Manu Kanwar, Brian Moldt, Mark Nagel, Craig S. Pace, YenRu Pan, Heather T. Stephenson, Nathan D. Thomsen
  • ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
    Publication number: 20220089698
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Application
    Filed: October 7, 2021
    Publication date: March 24, 2022
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • Antibodies that target HIV GP120 and methods of use
    Patent number: 11168130
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 9, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Mini Balakrishnan, Brian A. Carr, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES
    Publication number: 20210155676
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Application
    Filed: December 3, 2020
    Publication date: May 27, 2021
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 10882898
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: January 5, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 10882907
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 5, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
    Publication number: 20200377592
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Application
    Filed: May 6, 2020
    Publication date: December 3, 2020
    Inventors: Tomas Cihlar, Joshua Goldsmith, George Kukolj, Craig S. Pace, Doug Rehder, Derek Dean Sloan, Heather Theresa Stephenson, Nathan D. Thomsen
  • Multispecific antibodies that target HIV GP120 and CD3
    Patent number: 10836825
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: November 17, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE
    Publication number: 20200223907
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Application
    Filed: July 2, 2019
    Publication date: July 16, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Craig S. Pace, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Heather Theresa Stephenson, Nathan D. Thomsen, Helen Yu, Xue Zhang
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES
    Publication number: 20190211083
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Application
    Filed: February 12, 2019
    Publication date: July 11, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • Human immunodeficiency virus neutralizing antibodies
    Patent number: 10239935
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • MULTISPECIFIC ANTIBODIES THAT TARGET HIV GP120 AND CD3
    Publication number: 20180371086
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Applicant: Gilead Sciences, Inc.
    Inventors: Tomas Cihlar, Joshua Goldsmith, Craig S. Pace, Derek Sloan, Heather Stephenson, Nathan D. Thomsen, George Kukolj, Doug Rehder